Document:

EX-10.68

June 16, 2008

	 	 	 	 	 
	GlaxoSmithKline
	 	 	 	 
	2301 Renaissance Boulevard

	Building #510
RN0420
	 	 	 	 
	King of Prussia, Pennsylvania 19406

	Attn:
	 	Vinod Ramachandran, Ph.D.

Alliance Manager

Re: Third Extension of the Research Term with respect to CENP-E under that certain Collaboration
and License Agreement by and between Glaxo Group Limited, a GlaxoSmithKline company,
(“GSK”) and Cytokinetics, Inc. (“CK”), dated June 20, 2001, as amended (the
“Collaboration Agreement”)

Dear Vinod:

Pursuant to this letter amendment to the Collaboration Agreement (the “Amendment”), GSK and
CK desire to further extend the Research Term solely with respect to the Mitotic Kinesin Target
known as CENP-E, and on the terms set forth herein.

Now therefore, GSK and CK agree, effective as of June 19, 2008, as follows:

	 	1.	 	All capitalized terms not defined herein shall have the meaning ascribed to them in
the Collaboration Agreement.

	 	2.	 	Notwithstanding GSK’s obligation to notify CK in writing of its exercise of its
option to extend the Research Term under Section 2.8.1 of the Collaboration Agreement, the
Research Term is hereby extended for an additional one-year period to expire on June 19,
2009 solely with respect to CENP-E to allow for the conduct of Research Program activities
directed to CENP-E, in accordance with the terms and conditions of the Collaboration
Agreement. GSK shall have no further right to extend the Research Term, unless otherwise
expressly agreed in writing by the Parties.

	 	3.	 	GSK shall have no further right to extend its exclusivity rights under Section 4.2 of
the Collaboration Agreement with respect to CENP-E, unless otherwise expressly agreed in
writing by the Parties.

	 	4.	 	The Research Plan for the extended Research Term is attached as Exhibit A hereto.

	 	5.	 	Notwithstanding Section 2.8.1 of the Collaboration Agreement, GSK has no obligation
to fund any CK FTEs during this extension of the Research Term for CENP-E.

	 	6.	 	Each Party agrees to execute, acknowledge and deliver such further instruments, and
to do all such other acts, as may be necessary or appropriate in order to carry out the
purposes and intent of this Amendment.

	 	7.	 	Except as specifically modified or amended hereby, the Collaboration Agreement shall
remain in full force and effect and, as modified or amended, is hereby ratified, confirmed
and approved. No provision of this Amendment may be modified or amended except expressly
in a writing signed by both Parties, nor shall any terms be waived except expressly in a
writing signed by the Party charged therewith. This Amendment shall be governed in
accordance with the laws of the State of New York, without regard to principles of
conflicts of laws.

If the foregoing is acceptable, please have an authorized representative of GSK countersign this
Amendment where indicated below. Please return one fully executed original to my attention.

Sincerely,

/s/ Michael S. Rabson

Michael S. Rabson, Ph.D.

Sr. Vice President, Business Development & Legal Affairs, and General Counsel

Cytokinetics, Inc.

Agreed and accepted:

GLAXO GROUP LIMITED

/s/ Paul Williamson

For and on behalf of

Edinburgh Pharmaceutical Industries Limited

Corporate Director

/s/ Paul Blackburn

For and on behalf of

Glaxo Group Limited

Corporate Director

18/6/08

	 	 	 
	cc:

	 	Adrian Rawcliffe, SVP WW Business Development, GlaxoSmithKline

Lisa A. DeMarco, Esq., VP & Associate General Counsel, GlaxoSmithKline,

R&D Legal Operations

1

Exhibit A

Research Plan 

[****]

2

[***]

3EX-10.68

June 16, 2008

	 	 	 	 	 
	GlaxoSmithKline
	 	 	 	 
	2301 Renaissance Boulevard

	Building #510
RN0420
	 	 	 	 
	King of Prussia, Pennsylvania 19406

	Attn:
	 	Vinod Ramachandran, Ph.D.

Alliance Manager

Re: Third Extension of the Research Term with respect to CENP-E under that certain Collaboration
and License Agreement by and between Glaxo Group Limited, a GlaxoSmithKline company,
(“GSK”) and Cytokinetics, Inc. (“CK”), dated June 20, 2001, as amended (the
“Collaboration Agreement”)

Dear Vinod:

Pursuant to this letter amendment to the Collaboration Agreement (the “Amendment”), GSK and
CK desire to further extend the Research Term solely with respect to the Mitotic Kinesin Target
known as CENP-E, and on the terms set forth herein.

Now therefore, GSK and CK agree, effective as of June 19, 2008, as follows:

	 	1.	 	All capitalized terms not defined herein shall have the meaning ascribed to them in
the Collaboration Agreement.

	 	2.	 	Notwithstanding GSK’s obligation to notify CK in writing of its exercise of its
option to extend the Research Term under Section 2.8.1 of the Collaboration Agreement, the
Research Term is hereby extended for an additional one-year period to expire on June 19,
2009 solely with respect to CENP-E to allow for the conduct of Research Program activities
directed to CENP-E, in accordance with the terms and conditions of the Collaboration
Agreement. GSK shall have no further right to extend the Research Term, unless otherwise
expressly agreed in writing by the Parties.

	 	3.	 	GSK shall have no further right to extend its exclusivity rights under Section 4.2 of
the Collaboration Agreement with respect to CENP-E, unless otherwise expressly agreed in
writing by the Parties.

	 	4.	 	The Research Plan for the extended Research Term is attached as Exhibit A hereto.

	 	5.	 	Notwithstanding Section 2.8.1 of the Collaboration Agreement, GSK has no obligation
to fund any CK FTEs during this extension of the Research Term for CENP-E.

	 	6.	 	Each Party agrees to execute, acknowledge and deliver such further instruments, and
to do all such other acts, as may be necessary or appropriate in order to carry out the
purposes and intent of this Amendment.

	 	7.	 	Except as specifically modified or amended hereby, the Collaboration Agreement shall
remain in full force and effect and, as modified or amended, is hereby ratified, confirmed
and approved. No provision of this Amendment may be modified or amended except expressly
in a writing signed by both Parties, nor shall any terms be waived except expressly in a
writing signed by the Party charged therewith. This Amendment shall be governed in
accordance with the laws of the State of New York, without regard to principles of
conflicts of laws.

If the foregoing is acceptable, please have an authorized representative of GSK countersign this
Amendment where indicated below. Please return one fully executed original to my attention.

Sincerely,

/s/ Michael S. Rabson

Michael S. Rabson, Ph.D.

Sr. Vice President, Business Development & Legal Affairs, and General Counsel

Cytokinetics, Inc.

Agreed and accepted:

GLAXO GROUP LIMITED

/s/ Paul Williamson

For and on behalf of

Edinburgh Pharmaceutical Industries Limited

Corporate Director

/s/ Paul Blackburn

For and on behalf of

Glaxo Group Limited

Corporate Director

18/6/08

	 	 	 
	cc:

	 	Adrian Rawcliffe, SVP WW Business Development, GlaxoSmithKline

Lisa A. DeMarco, Esq., VP & Associate General Counsel, GlaxoSmithKline,

R&D Legal Operations

1

Exhibit A

Research Plan 

[***]

*** Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

2

[***]

*** Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

3EX-10.1

EXHIBIT 10.1

FIRST AMENDMENT TO

SERVICES AGREEMENT

This First Amendment To Services Agreement (this “Amendment”) is dated June
20, 2008 (the “First Amendment Effective Date”) by and among the following parties:

(1) CPI International Touring Inc. (“Touring ROW”), a Barbados IBC corporation;

(2) KSC Consulting (Barbados) Inc. (“KSC”), a Barbados corporation;

(3) Live Nation Worldwide, Inc. (“LN”), a Delaware corporation, on its own behalf and
in its capacity as successor-in-interest to each of CPI Touring (USA), Inc., a Delaware
corporation, CPI Entertainment Content (2005), Inc., a Delaware corporation, CPI Entertainment
Content (2006), Inc., a Delaware corporation and Grand Entertainment (ROW), LLC, a Delaware limited
liability company (collectively with Touring ROW, the “CPI Companies”); and

(4) Michael Cohl, a resident of Barbados (“Cohl”).

RECITALS

Whereas, the CPI Companies (collectively and together with LN, the
“Companies”), KSC and LN are parties to that certain Services Agreement (the “Services
Agreement”) executed on September 12, 2007; and

Whereas, the Companies, KSC and Cohl have agreed to amend certain provisions in the
Services Agreement as more fully set forth herein.

AMENDMENT

Now, Therefore, in consideration of the mutual promises and obligations contained
herein, the parties agree as follows:

1. Modification of Term. Section 1(a) of the Services Agreement is hereby amended and
restated in its entirety to read as follows:

(a) Term. Unless earlier terminated in accordance with the provisions of Section 6 hereof,
the Services Relationship starts on the Effective Date and ends on the close of business on
the fourth (4th) anniversary of the First Amendment Effective Date.

2. Modification of Title and Reporting. Section 2(a) of the Services Agreement is hereby
amended and restated in its entirety to read as follows:

(a) Title and Reporting. During the Actual Term, the following provisions will apply:

(i) As of the First Amendment Effective Date, Cohl hereby resigns as the Chief
Executive Officer of each of the CPI Companies and all other offices of the Companies and
Live Nation, Inc. As of the First Amendment Effective Date, the employees of each of the
CPI Companies shall no longer report directly to Cohl and Cohl shall have no day-to-day
management responsibilities or authority over any such employees or operations. LN will
continue to have the right to dissolve any one or more of the CPI Companies and/or assign
all or any portion of the assets of the CPI Companies to other affiliates of LN.

(ii) Cohl will serve as a consultant to the Companies, including, without limitation,
to LN’s division known as Live Nation Artists or Artist Nation (the “Artist Nation
Division”).

(iii) In his capacity as a consultant, Cohl will report solely to LN’s Chief Executive
Officer.

3. Modification of Duties and Authority. Section 2(b) of the Services Agreement is hereby
amended and restated in its entirety to read as follows:

(b) Duties and Authority. KSC will cause Cohl to perform such consulting duties for the
Companies that any of the Companies may from time to time reasonably and lawfully designate
and that are mutually agreed upon by the parties.

4. Certain Deletions in Section 2. Sections 2(c), 2(d), 2(e) and 2(g) of the Services
Agreement are hereby deleted in their entirety.

5. Compensation. Section 3 of the Services Agreement is hereby amended and restated in its
entirety to read as follows:

3. COMPENSATION.

The Companies will pay to KSC, in a lump sum within five business days of full
execution of this Amendment, an upfront cash payment of $4.5 million as compensation for the
services to be provided hereunder. Such payment shall not be refundable, subject to offset
or otherwise returnable to the Companies under any circumstances whatsoever. The payment of
such amount shall be the joint and several obligation of the Companies, and the Companies
will allocate the responsibility of such payment among themselves as they may mutually agree
from time to time based upon the relative amount of services provided hereunder by Cohl to
each Company.

6. Termination. Section 6 of the Services Agreement is hereby amended and restated in its
entirety to read as follows:

6. TERMINATION.

The Services Relationship shall terminate on the fourth anniversary of the First
Amendment Effective Date without any action or notice required by any party hereto, unless
extended upon the mutual written agreement of the parties. The Companies may terminate the
Services Relationship at any time and for any reason, with or without cause, upon written
notice to KSC, and upon any termination the Companies shall have no obligation to KSC or
Cohl whatsoever, including for compensation or otherwise. Notwithstanding any termination
of the Services Relationship pursuant to this Section 6, the provisions of Sections 4, 5, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and 19 of this Agreement will survive such
termination.

7. Compensation Upon Termination. Section 7 of the Services Agreement is hereby deleted in
its entirety.

8. Insurance. Section 12(b) is hereby deleted in its entirety.

9. Director Severance Event. As of the First Amendment Effective Date, Cohl hereby resigns
as a director of the LN Board. The parties hereto agree that as of the First Amendment Effective
Date, a “Director Severance Event” has occurred under the Services Agreement and, as such, the
obligations under Section 2(f) of the Services Agreement will no longer apply.

10. Venue for Performance. Any and all consulting services to be provided to the Companies
by Cohl hereunder may be performed by Cohl from Barbados, and nothing herein shall require Cohl to
travel to or be present in the United States of America or elsewhere to perform any such services
hereunder.

11. Public Announcements.

(a) Except as may be required by applicable law, neither KSC nor Cohl shall issue any press
release or otherwise make any public statements or filings with respect to this Amendment or the
transactions contemplated hereby without the prior written consent of LN.

(b) Except as may be required by applicable law or as may be required to satisfy the rules of
any listing exchange upon which the common stock of LN Parent is listed, none of the Companies or
any of their respective Affiliates will issue a separate stand-alone press release or public
announcement that describes the terms of this Amendment unless Cohl has reviewed and approved such
stand-alone press release or public announcement (such approval not to be unreasonably withheld or
delayed). The Companies and their respective Affiliates shall not be otherwise restricted or
constrained in any public statement concerning the provisions of this Amendment that is made as a
part of an earnings release, investor call or other similar communication that includes disclosures
or discussions about matters other than the transaction contemplated hereby.

12. Release. As a condition to entering into, and in exchange for the promises and
consideration contained in this First Amendment, Cohl, the Companies and KSC are concurrently
entering into a general release of claims related to prior periods.

13. No Other Amendment. Except as expressly amended hereby, the terms, provisions,
covenants, restrictions and other agreements contained in the Services Agreement are hereby
ratified, confirmed and carried forward in all respects. For the avoidance of doubt, such sections
of the Services Agreement that remain unamended and in full force and effect include, without
limitation, Sections 4 and 5 related to nondisclosure of confidential information and protective
covenants, respectively.

14. Captions and Headings. The captions and headings used in this Amendment are for
convenience purposes only and will not in any way affect the meaning or interpretation hereof.

15. Counterparts. This Amendment may be executed (manually or by facsimile or similar
electronic means) in any number of counterparts, each of which for all purposes shall be deemed an
original, but all of which together will constitute but one and the same instrument.

[Signatures Appear on the Following Page]

1

In Witness Whereof, the parties have duly executed and delivered this Amendment as of
the date first written above.

	 	 	 	CPI International Touring Inc.,

a Barbados IBC corporation

	 	 	 	By:
/s/ Michael Rapino

	 	 	Michael Rapino, President

	 	 	 	KSC Consulting (Barbados) Inc.,

a Barbados corporation

	 	 	 	By:
/s/ Michael Cohl

	 	 	Michael Cohl, President

	 	 	 	Live Nation Worldwide, Inc.,

a Delaware corporation

	 	 	 	By: /s/ Michael Rapino

	 	 	Name:
Michael Rapino

	 	 	 	Title: President and Chief Executive Officer

	 	 	 	Michael Cohl

	 	 	 	/s/ Michael Cohl

	 	 	Michael Cohl

Live Nation, Inc., joins in the execution of this Agreement solely for the purposes of
acknowledging this Amendment.

By: /s/ Michael Rapino          

Name: Michael Rapino

Title: President and Chief Executive Officer

[Signature Page to the First Amendment to Services Agreement]

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}]]